Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8540489 | 0.86 | ALDH1A1 (0.47) | GRIN1MEN1LMNACYP1A2KMT2A | |
| SCHEMBL4345218 | 0.78 | MEN1 (0.54) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL8465056 | 0.76 | GRIN1 (0.54) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL4342185 | 0.76 | GRIN1 (0.66) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL9583009 | 0.75 | GRIN1 (0.51) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL4343874 | 0.75 | MEN1 (0.47) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL4480896 | 0.73 | GRIN1 (0.53) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL8539180 | 0.73 | GRIN1 (0.47) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL8542908 | 0.72 | GRIN1 (0.46) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL4342139 | 0.71 | MEN1 (0.47) | GRIN1MEN1LMNACYP1A2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. | 2008-06-05 | — | — | US | claimed |
| EP-1501797-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040006123-A1 | Interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-01-08 | — | — | US | claimed |
| WO-2003091214-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO | AVENTIS PHARMACEUTICALS INC. (US) | 2003-11-06 | — | — | WO | claimed |
| US-5189054-A | 3-amidoindolyl derivatives and pharmaceutical compositions thereof | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-02-23 | — | — | US | claimed |
| EP-1501797-B1 | 3-(SUBSTITUTED AMINO)-1H-INDOLE-2-CARBOXYLIC ACID ESTER AND 3-(SUBSTITUTED AMINO)-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID ESTER DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMA INC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1501797-B1 | 3-(SUBSTITUTED AMINO)-1H-INDOLE-2-CARBOXYLIC ACID ESTER AND 3-(SUBSTITUTED AMINO)-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID ESTER DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMA INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. | 2008-06-05 | — | — | US | disclosed |
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. | 2008-06-05 | — | — | US | disclosed |
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. | 2008-06-05 | — | — | US | disclosed |
| EP-1834947-A2 | 3-substituted amino-1H-indole-2-carboxylic acid and 3-substituted amino-benzo[B]thiophene-2carboxylic acid derivatives as interleukin-4 gene expression inhibitors | Aventis Pharmaceuticals, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1834947-A2 | 3-substituted amino-1H-indole-2-carboxylic acid and 3-substituted amino-benzo[B]thiophene-2carboxylic acid derivatives as interleukin-4 gene expression inhibitors | Aventis Pharmaceuticals, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2003091215-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO’ B! THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERIEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003091214-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO | AVENTIS PHARMACEUTICALS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-0483881-B1 | 3-Amidoindolyl derivatives | MERRELL PHARMA INC (US) | 1998-01-21 | — | — | EP | disclosed |
| US-5703107-A | CENTRAL NERVOUS SYSTEM DISORDERS; ANALGESICS; ANTIEPILEPTIC AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1997-12-30 | — | — | US | disclosed |
| US-5675018-A | 3-amidoindolyl derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1997-10-07 | — | — | US | disclosed |
| US-5491153-A | 3-amidoindolyl derivative | MERRELL DOW PHARMACEUTICALS INC. (US) | 1996-02-13 | — | — | US | disclosed |
| US-5189054-A | 3-amidoindolyl derivatives and pharmaceutical compositions thereof | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-02-23 | — | — | US | disclosed |
| EP-0483881-A1 | 3-Amidoindolyl derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006123-A1 | Interleukin-4 gene expression inhibitors | IL4, STAT4, BCL6 | GRIN1 3912/4885MEN1 4076/4885LMNA 4805/4885 |
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | IL4, STAT4, STAT6 | GRIN1 4181/4885MEN1 4032/4885LMNA 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.